Patients with multiple myeloma (MM) who undergo autologous stem cell transplantation (ASCT) are susceptible to severe infections. Low levels of circulating mannan-binding lectin (MBL) are associated with increased risk of infection. In this prospective study, we evaluated 100 patients who underwent ASCT regarding the effect of MBL on the incidence and severity of febrile episodes. Seventeen patients had MBL levels o500 ng/mL (11 received antibiotic prophylaxis and 6 did not). Although there was no statistical difference regarding the development of febrile episodes between patients with low and normal MBL, among 17 patients with low MBL levels, six out of eleven patients who received antibiotic prophylaxis developed a febrile episode compared with six out of six patients who did not receive antibiotic prophylaxis and developed a febrile episode. Patients with low MBL levels who responded less frequently to first line antibiotic therapy required more frequent administration of a second more advanced line of antibiotics, independently of receiving or not prophylaxis, and required prolonged hospitalization. In the univariate analysis low MBL associated with shorter OS. Our results suggest that patient with low MBL levels should receive antibiotic prophylaxis to reduce the number of febrile episodes and raise the issue of MBL replacement for these patients.
INTRODUCTION
Recurrent infections are a common symptom of multiple myeloma. 1, 2 The disease itself often compromises several modalities of the immune defense system 3 including T-cell functions, bone marrow function and the production of polyclonal antibodies. 4 Patients receiving chemotherapy suffer from significant morbidity and mortality due to additional chemotherapyinduced immunosuppression.
High dose melphalan (HDM) with autologous stem cell support (ASCT) is the recommended treatment for MM patients ⩽ 65 years of age. In total 80% of patients may develop neutropenic fever after stem cell reinfusion, while up to one third of them have culture positive infections. 5 The mannan-binding lectin (MBL) pathway of the complement system is part of the innate immune system 6, 7 and seems to affect the risk of infections not only for healthy individuals, 8, 9 but also of cancer patients during treatment. 10 In contrast to the classical complement pathway, the MBL pathway is not antibodydependent. MBL is a protein that belongs to the collectin family and is produced by hepatocytes. MBL acts via binding to the surface of bacteria and other pathogen factors, thus facilitating complement activation with formation of the membrane attack complex, leading to microbial lysis. 11 Besides microbes, MBL has been shown to bind to a wide range of microorganisms including fungi, protozoa and viruses. 12 The serum level of MBL is dependent on various factors such as polymorphisms, ethnicity and age. In the general population, 15-20% of people have MBL levels o 500 ng/mL, while even lower levels ( o100 ng/mL) are associated with increased frequency of infections. 13 The impact of the MBL on the occurrence of infections during chemotherapy in malignant diseases has been widely explored in different studies with conflicting results. The aim of this study was to evaluate the impact of serum MBL levels on the risk of infections, the risk of development of febrile episodes and their severity in patients with MM who receive HDM and ASCT.
PATIENTS AND METHODS
This was a prospective study for the evaluation of circulating levels of MBL in myeloma patients who underwent an ASCT.
Inclusion and exclusion criteria
The inclusion criteria of the study included: (i) adult patients with newly diagnosed symptomatic myeloma (NDMM) who undergo an ASCT; (ii) patients who have a sufficient peripheral blood stem cell collection (43x10 6 CD34 + cells/kg); (iii) patients who have given their written informed consent for blood sampling and for recording of their medical data which is pertinent to the purposes of this study.
The exclusion criteria included: (i) patients o18 years; (ii) the presence of HIV or hepatitis B and C that alters the measurement of MBL; (iii) the presence of autoimmune disorders, that is, systemic lupus erythematosus; (iv) the presence of renal dysfunction or use of thyroid hormones that could alter the levels of MBL during the last six months before measurement. The participation of the patients in another clinical trial was not an exclusion criterion for participation in the study.
Study endpoints
The primary endpoint of the study was the evaluation of febrile episodes among MM patients with low or normal MBL levels during their hospitalization for the administration of high dose melphalan and ASCT. Secondary endpoints included differences among patients with low and normal MBL levels during the same time period regarding: (i) number and type of infectious episodes; (ii) severity of infectious episodes; (iii) incidence of bacteremia; (iv) number of days of hospitalization; (v) number of days with fever; (vi) in case of febrile episode response to first line antibiotics therapy; (vii) transplantation related morbidity and mortality; (viii) PFS and overall survival (OS).
Patient enrollment
The enrollment period was between June 1996 and January 2011. Patients were informed of the objectives and the details of the study before giving their approval and signing the informed consent forms. The study was conducted according to the principles defined by the 18th World Medical Association Assembly (Declaration of Helsinki, 1964 ) and all its future amendments. The study protocol was designed and executed according to the guidelines and regulations pertaining to studies in Greece, as well as the Good Clinical Practice Guidelines as defined by the International Conference of Harmonization. The study was approved by the local ethics committee.
Data recording and quality assurance Data were collected from the medical files of the enrolled patients. Clinical study monitoring was performed for source data verification and ensured the accuracy of the data.
MBL measurement
MBL serum levels were measured after drawing a blood sample in all patients on the day of mobilization, before the administration of cyclophosphamide, by a commercially available MBL oligomer ELISA kit, according to the manufacturer's instructions (R&D Systems, Minneapolis, MN, USA). All blood samples were centrifuged at 3000 r.p.m. for 10 min and stored at − 80°C, till the day of measurement. According to the manufacturer, the cut-off value of 500 ng/mL of serum MBL was used to form two groups of patients, those with low MBL ( o500 ng/mL) and those with high/normal MBL levels (⩾500 ng/mL).
Statistical analysis
Differences between patient subsets were evaluated using the Mann-Whitney test. The Spearman Rank correlation test was employed to examine relationships between various parameters. Logarithmic transformation was also used for heavily skewed variables. In addition, multiple logistic regression analyses were made by using breakthrough fever (yes/no) and bacteremia (yes/no) as dependent variables. Survival was calculated from the day of treatment initiation until the date of death or last follow-up. Patients who were lost to follow-up were censored at the date of last contact. Survival probabilities were calculated by the Kaplan-Meier method and comparisons made using the log-rank test. All P values were two sided, the level of significance was o0.05 and confidence intervals refer to 95% boundaries. All analyses were performed using SPSS 20 software.
RESULTS

Patients
One hundred patients participated in this study (Table 1) . All patients had a sufficient peripheral blood stem cell collection (45 × 10 6 CD34 + cells/kg) and underwent a single ASCT. All patients received high-dose therapy with intravenous melphalan 200 mg/m 2 , administered one day before stem cell reinfusion. All patients received prophylactic therapy with 200 mg fluconazole daily and 500 mg valacyclovir daily. In total 67% patients participated in a randomized two arm study, where in the arm A patients received prophylactic antibiotics, including vancomycin at a dosage of 1 g once daily and ciprofloxacin at a dosage of 400 mg twice daily, while in the arm B there was no antibiotic prophylaxis. All patients received G-CSF 480 μg twice daily from day of stem cell reinfusion to neutrophil counts 41500/mm 3 . In case of neutropenic fever, prophylactic antibiotics were interrupted and first line regimen was administered, including vancomycin 1 g twice daily, amikacin 500 mg twice daily and ceftazidime 2 g every 8 h. In the case of failure of first line treatment, a second line antibiotic combination was administered, usually including a carbapenem and linezolid. Antibiotic regimens were also modified according to results of blood or urine cultures (sensitivity to the aforementioned antibiotics).
Study endpoints
In total 17% patients had MBL levels o 500 ng/mL. Of those, 11 received antibiotics prophylaxis and 6 did not. In total 83% patients had MBL levels ⩾ 500 ng/mL, respectively. Regarding infectious complications (Table 2) , there was no statistical difference regarding the development of febrile episodes between patients with MBL serum levels of o500 ng/mL or ⩾ 500 ng/mL (12/17 vs 62/83; P = 0.664) (Figure 1 ). However, among 17 patients with MBL levels of o 500 ng/mL, six out of eleven patients who received antibiotics prophylaxis developed a febrile episode compared with six out of six patients who did not receive antibiotics prophylaxis and developed a febrile episode, respectively (P = 0.049) (Figure 2 ). There was no difference in the incidence of septicemia (30.8% vs 33.8%, P = 0.83), the severity of infection (P = 0.872), the number of days of hospitalization or the number of days with fever between patients with MBL serum levels of o500 ng/mL or ⩾ 500 ng/mL (P40.05). There was no difference in the frequency of fever resolution within 7 days, among patients with MBL serum levels of o 500 ng/mL or ⩾ 500 ng/mL (P = 0.647). Moreover there was no difference in lower respiratory tract infections in patients with MBL serum levels of o 500 ng/mL or ⩾ 500 ng/mL (P = 0.185). Nevertheless, patients with MBL levels o500 ng/mL attained a lower response rate to first line therapy with antibiotics, that is, lower percentage of fever resolution and higher incidence of necessary administration of a second line antibiotic regimen, compared with patients with MBL levels of ⩾ 500 ng/mL (66.7% (8/12) vs 88.9% (48/54) ( Figure 3 ), respectively; P = 0.045). These patients required prolonged hospitalization, compared with patients who did respond to first line antibiotics (median hospitalization 22 vs 18 days, P = 0.01) ( Table 3) .
Despite the fact that there was no statistically significant difference in the incidence of bacteremia (58.3% vs 69.2% P = 0.352), patients who did not respond to first line antibiotics suffered from prolonged median neutropenic fever interval (14 vs 10 days, P o 0.001) and gastrointestinal toxicity, in comparison to patients who did respond to first line antibiotics. MBL levels were not associated with the incidence of stomatitis (P = 0.628), diarrhea (P = 0.661), or vomiting (P = 0.916), irrespectively of receiving or not prophylactic antibiotics (Table 4 ). In the univariate analysis, there was a borderline significant difference in median overall survival among patients with serum MBL levels Figure 2 . Neutropenic fever for patients with MBL levels o500 ng/mL, regarding prophylaxis or no prophylaxis. Low MBL levels and febrile episodes in ASCT for Myeloma E Eleutherakis-Papaiakovou et al o500 ng/mL and 4 = 500 ng/mL (57.1 months (95% CI: 48.1-66.2) vs 84.0 months (95% CI: 74-94); P = 0.064), which did not retain independent prognostic value in the multivariate analysis.
DISCUSSION
There is a vast amount of data supporting the key role of MBL in innate immunity mechanisms against microbes, including phagocytosis. 14 In daily practice, most MBL deficient recipients are healthy, since they have alternative mechanisms for antimicrobial protection. However MBL deficiency related to mutations on MBL coding gene that result in reduced plasma levels of mannose binding lectin 15 can be rendered a potent risk factor for developing infectious diseases in immunocompromised patients. 16 Other studies underscore the importance of low levels of MBL in developing septic shock connected to acute pyelonephritis. 17 Administration of chemotherapy has been associated with immunosuppression by damaging mucosal barriers and impairing both innate and specific cellular immunity [18] [19] [20] thus highlighting the importance of intact mechanisms of innate immunity, such the system of lectins. A lot of studies underscore the association of MBL status with the risk of major infection in cancer patients receiving chemotherapy. Nazari et al. 21 have confirmed the association of MBL and MASP-2 deficiency with increased risk of febrile neutropenia in leukemic children treated with chemotherapy.
Additional data confirm MBL serum levels' importance in patients undergoing autologous or allogeneic transplantation. Mulighan et al. 22 have reported that MBL coding mutations that reduce MBL serum levels were associated with major infection in recipients receiving myeloablative, TBI-conditioned allogeneic transplantation. Their data are in accordance with data published by Horiuchi et al. 23 , in patients treated with high-dose chemotherapy and autologous PBSCT.
Regarding MM patients, Molle et al. 24 have already reported data confirming the negative impact of MBL2 gene polymorphisms, which reduce levels of active serum MBL, on the incidence of severe infection in patients with MM receiving conventional chemotherapy (VAD or Cydex). In another study the same investigator noticed that MBL2 polymorphisms, leading to low serum levels and less functional MBL oligomers, were related to increased risk of severe infections in MM patients receiving high-dose melphalan and autologous stem cell transplantation, but not with breakthrough fever in general. 25 Despite the vast amount of data supporting the correlation of MBL serum levels to infections, there are also reports that cannot confirm the impact of MBL levels on the incidence of chemotherapy-related infections. Kilpatric and colleagues could not confirm any correlation between MBL, L-ficolin or H-ficolin concentration and febrile neutropenia expressed as the proportion of neutropenic periods in which patients experienced fever or relation between abnormally low (deficiency) levels of MBL, L-ficolin or H-ficolin and febrile neutropenia expressed. 26 Our prospective study focused on the impact of MBL levels on the occurrence of febrile episodes and infections severity in a large series of MM patients undergoing ASCT. The study group was homogenous with respect to the chemotherapy treatment used (chemotherapeutic agent and dosage), and no important difference in co-variables was found between the two subgroups of patients (with low and normal MBL levels). All our patients were hospitalized in our center for receiving after high dose therapy and until hematopoietic recovery, thus facilitating patients close follow up during the early post-transplant period.
Patient who undergo ASCT and receive high dose therapy usually suffer from severe mucositis 27 that disrupts the mechanical and biological barrier that mucosa represents, underlying the importance of serum factors that play role in the successful restriction of early infection like MBL. The vast majority of our patients developed neutropenic fever (84% and many of them were diagnosed with bacteremia), as also reported by previous studies regarding infectious complications during neutropenia subsequent to peripheral blood stem cell transplantation. [28] [29] [30] [31] The results of measurement of MBL levels at stem cell mobilization cannot confirm that low levels of serum MBL are strongly associated with increased incidence of febrile episodes, as already Low MBL levels and febrile episodes in ASCT for Myeloma E Eleutherakis-Papaiakovou et al reported in previous studies. However, the most striking result from our study is that myeloma patients who underwent ASCT and had low levels of MBL had a lower response rate to first line antibiotic regimens, requiring more often administration of a second more advanced line of antibiotics, independently of receiving or not prophylaxis. These patients required prolonged hospitalization and had prolonged median neutropenic fever interval and gastrointestinal toxicity. Furthermore, the administration of prophylactic antibiotics to these patients reduced the number of febrile episodes as already mentioned in previous studies. [32] [33] [34] [35] The protective effect of prophylactic antibiotics was equally potent to both subgroups studied (patient with MBL ⩾ or o500 ng/mL), overcoming the negative impact of low MBL levels, expressed as less often response in first line antibiotic treatment. Administration of prophylactic antibiotics during transplantation is not recommended for all patients, underlining the importance of distinguishing subgroups that are in a significantly greater danger from severe infections. Patients in the subgroup of low MBL levels could attain the maximum gain from pre-emptive (prophylactic) administration of antibiotics among all patients, suggesting that administration of prophylactic antibiotics could be justified for these patients who are more prone to lower response rate to first line antibiotics for already established infections. These data emphasize on different role for MBL than that of prompt response to initial stage of infection, 36 suggesting a synergistic activity with antibiotics in the management of established infections.
MBL replacement therapy has been explored for its clinical potential in order to reduce susceptibility to infections or alter the natural history of autoimmune diseases. The place of MBL replacement therapy cannot be established without solid results of randomized controlled clinical trials. 37, 38 In conclusion, our data highlight the importance of the innate immune system in permitting antibiotics to exercise their protective effect in severely immuno-compromised patients (patients undergoing ASCT) and raise the question about the necessity of administering prophylactic antibiotics in the subgroup of patients with low levels serum MBL, to prevent infections that require more advanced antibiotics to be restrained. Furthermore, our study raises the suggestion for MBL replacement therapy that could be useful to reduce the risk of infection or improve patients' response to antibiotics after transplantation.
